The Future of Vaccines
Watch the recording of this conversation here.
The future is now. 2020 presented us with challenges that we never could have predicted. Our industry was put to the test in terms of innovation and speed in vaccine development, and they delivered COVID-19 vaccines with novelty and success. What lies ahead for vaccines and the opportunities for new and developing companies? CvilleBioHub and the UVA-Coulter Translational Partnership explore expansions in vaccine development and discuss what the future landscape may look like for the biotechnology sector.
Kerrie DeMarco, Beyond the Needle Program Manager, BARDA
Phyllis Arthur, Vice President, Infectious Diseases and Diagnostics Policy, BIO
David Dillon, Vice President, Chief Financial Officer, Verndari Inc.
Tony Baker, Executive Director, Plant Management and Elkton Vaccine Operations Lead, Merck